Please login to the form below

Not currently logged in
Email:
Password:

Juno Therapeutics

This page shows the latest Juno Therapeutics news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

These include Juno Therapeutics’CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.

Latest news

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    s lymphoma developed by Juno Therapeutics, which was acquired by Celgene earlier this year. ... That includes data on Jounce Therapeutics’ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this

  • FDA turns down Celgene’s filing for multiple sclerosis drug FDA turns down Celgene’s filing for multiple sclerosis drug

    The company has responded to the difficult period with the $9bn acquisitions of Juno Therapeutics - giving it a stake in the emerging CAR-T cancer immunotherapy market - as well as paying

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    Celgene has agreed to acquire the 90% of CAR-T specialist Juno Therapeutics it doesn’t already own in a $9bn deal that, at a stroke, makes it a big player ... If that prediction comes true, the price tag for Juno looks like a bargain.

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    Is acquisitive Celgene now eyeing CAR-T specialist Juno? Rumours circulate just days after the US biotech confirms ImpactBio purchase. ... Celgene is in talks with Juno Therapeutics about a possible takeover deal, right after cutting a $7bn deal to buy

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    What happens next for Cellectis is hard to gauge. Another CAR-T developer - Juno Therapeutics - had its lead therapy JCAR015 placed under a clinical hold by the FDA after a patient

More from news
Approximately 7 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Pharma deals in July 2015 Pharma deals in July 2015

    It still sounds like a high price but perhaps it is in Celgene'sDNA because only a month ago it bought shares in Juno Therapeutics at over a 100% premium in

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Juno Therapeutics names Cindy Elkins as CIO. She joins the biopharma from Genentech, where she was VP of IT. ... Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics